Anatomic Pathology Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Anatomic Pathology Market Report is Segmented by Product & Services (Instruments, Consumables, and Services), Application (Disease Diagnosis, Drug Discovery & Development, and Other Applications), End User (Hospitals, Diagnostic Laboratories, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Anatomic Pathology Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Anatomic Pathology Market with other markets in Healthcare Industry

Anatomic Pathology Market Analysis by Mordor Intelligence

The anatomic pathology market is valued at USD 38.34 billion in 2025 and is projected to reach USD 56.65 billion by 2030, advancing at an 8.12% CAGR. Rising cancer incidence, continued technology upgrades, and wider precision medicine use sustain high test volumes and steady capital spending. Hospitals expand tissue-based diagnostics to support oncology programs while pharmaceutical companies embed companion diagnostics into late-stage trials, creating new revenue layers. Digital slide scanners, laboratory automation, and artificial intelligence cut turnaround time and partially offset staff shortages. Regulatory agencies strengthen quality expectations yet also accelerate clearances for digital pathology, encouraging faster adoption[1]World Health Organization, “Cancer burden rising,” who.int.

Key Report Takeaways

  • By product category, consumables led with 46.54% revenue share in 2024; services are forecast to expand at a 10.45% CAGR to 2030.
  • By application, disease diagnosis accounted for 62.34% of the anatomic pathology market share in 2024 while drug discovery and development is advancing at an 11.78% CAGR through 2030.
  • By end user, hospital settings held 43.23% of demand in 2024 and diagnostic laboratories record the highest projected CAGR at 11.34% to 2030.
  • By geography, North America captured 41.56% revenue share in 2024; Asia-Pacific is the fastest growing region at a 9.45% CAGR through 2030.

Segment Analysis

By Product & Services: Consumables Drive Recurring Revenue Models

Consumables held 46.54% revenue in 2024 because every tissue block requires reagents, stains, and slides. Rising test complexity boosts premium antibody and molecular kit demand, supporting steady incremental growth. Services post the fastest 10.45% CAGR to 2030 as outsourcing gains traction and specialized molecular assays exceed in-house bandwidth. Instruments move in step with lab expansions, with digital scanners and automated stainers mitigating staff gaps and lifting standardization. Quest Diagnostics notes that upfront digital readouts prevent diagnostic delay and improve inter-pathologist collaboration, highlighting efficiency gains.

The anatomic pathology market size for consumables is projected to reach USD 26.4 billion in 2030, equal to 46.6% of total value. In contrast, services are anticipated to account for 34% of the anatomic pathology market size at the end of the forecast horizon due to sustained double-digit growth. Consumable suppliers therefore pursue reagent-lease models, guaranteeing recurring revenue while easing customer capital strain.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Disease Diagnosis Dominance Amid Drug Development Acceleration

Disease diagnosis accounted for 62.34% of 2024 revenue because every surgical or biopsy specimen needs confirmation before treatment. Cancer remains the largest driver as guidelines urge molecular stratification for targeted therapy. Drug discovery and development is set to expand at an 11.78% CAGR as pharmaceutical pipelines depend on tissue biomarker validation and histopathology-driven safety studies.

The segment commanded 50% share of the anatomic pathology market size for immunohistochemistry kits in 2024, reflecting oncology’s testing intensity. Drug development activities will likely raise their share by 2030 as spatial omics and multiplex imaging migrate from research to regulated use. Laboratories therefore realign capital toward high-plex instruments and digital storage to comply with protocol requirements.

Anatomic Pathology Market: Market Share by Application
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospital Infrastructure Meets Laboratory Specialization

Hospitals generated 43.23% of 2024 demand due to embedded pathology units that support inpatient surgery and oncology boards. Yet diagnostic laboratories outpace other settings with an 11.34% CAGR through 2030, aided by scale, automation, and cross-regional logistics. Reference labs secure large vaccine or companion diagnostic contracts, while academic centers lead translational research and rare disease expertise.

Hospital budgets increasingly favour outsourcing of molecular testing when case volume does not justify platform ownership. Diagnostic labs thus extend courier networks and remote sign-out portals, giving clinicians next-day answers and maintaining the anatomic pathology market share trend toward specialized providers. Workforce shortages accelerate this shift, especially in rural or tier-3 cities where lab technologist supply is thin.

Geography Analysis

North America commanded 41.56% revenue in 2024 owing to high cancer screening rates, established reimbursement, and early digital adoption. US healthcare spending surpasses USD 4 trillion, and pathology influences two-thirds of clinical decisions, solidifying service demand. Workforce programs from the American Society for Clinical Pathology focus on scholarship funding and reimbursement advocacy, though vacancies remain in double digits.

Asia-Pacific delivers the fastest 9.45% CAGR through 2030. China’s healthcare outlays reached 8.53 trillion yuan in 2022 and may pass 20 trillion yuan by 2030, boosting laboratory build-outs across provincial centers. Japan embeds AI imaging within routine pathology workflows to cut manual fatigue, and India’s diagnostic chains expand into tier-4 towns to capture preventive testing demand. Telepathology pilots link remote hospitals to central labs, improving access without duplicating infrastructure.

Europe shows steady uptake as digital slide standards and quality frameworks gain momentum under the European Society of Pathology. Only 3% of UK departments report full staffing, creating urgency for automated coverslippers and AI triage tools. Middle East & Africa and South America lag on large instrument investment, yet mobile slide scanners and cloud portals are spreading, enabling gradual participation in the anatomic pathology market.

Anatomic Pathology Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The sector is moderately consolidated. Roche, Danaher’s Leica Biosystems, and Thermo Fisher Scientific package instruments, reagents, and software into closed ecosystems that lock in consumable pull-through. Danaher posted USD 23.9 billion 2023 revenue with sizeable diagnostics exposure and is co-developing smart microscopy with Stanford for automated cell classification. Thermo Fisher’s USD 4.1 billion Solventum acquisition bolsters filtration and bio-production segments, while its USD 3.1 billion Olink deal broadens proteomics, creating synergy with tissue assays.

Emerging firms centre on cloud-native slide management and AI. Ibex Medical Analytics earned FDA clearance for prostate cancer algorithms that outperform manual review on small glandular foci. Microsoft’s GigaPath applies large-language techniques to gigapixel images, hinting at cross-discipline expansion. Investment flows into software over hardware, although integrated vendors quickly partner to fold algorithms into scanner ecosystems, as seen in Leica’s funding of Indica Labs for a combined Aperio-HALO AP solution.

Laboratories also consolidate. Quest Diagnostics and Sonic Healthcare add specialty hubs, aiming to dominate high-complexity testing while local hospital labs retain rapid histology. Automation suppliers use reagent bundling and managed services to protect margins in a price-sensitive climate.

Anatomic Pathology Industry Leaders

  1. Thermo Fisher Scientific Inc.

  2. Quest Diagnostics Incorporated

  3. F. Hoffmann-La Roche Ltd.

  4. Laboratory Corporation of America Holdings

  5. Agilent Technologies, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Anatomic Pathology Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: Thermo Fisher Scientific disclosed plans to divest parts of its diagnostics unit for about USD 4 billion, signalling portfolio realignment.
  • May 2025: Roche launched the Elecsys PRO-C3 test that delivers liver fibrosis status within 18 minutes, reducing the need for invasive biopsies.
  • April 2025: Roche obtained FDA breakthrough device designation for the Ventana TROP2 RxDx Device, the first AI-driven companion diagnostic in lung cancer.
  • March 2025: The FDA cleared Epredia’s digital pathology solution for primary diagnosis of surgical pathology slides.
  • February 2025: Thermo Fisher Scientific agreed to acquire Solventum’s Purification & Filtration business for USD 4.1 billion, targeting USD 125 million adjusted operating income by year five.

Table of Contents for Anatomic Pathology Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Cancer and Chronic Diseases
    • 4.2.2 Growing Adoption of Precision and Personalized Medicine
    • 4.2.3 Continuous Technological Advancements in Pathology Instruments And Automation
    • 4.2.4 Increasing Integration of Digital Pathology and Artificial Intelligence
    • 4.2.5 Expansion of Molecular and Spatial Omics in Routine Histopathology
    • 4.2.6 Emergence of Telepathology Networks in Resource-Limited Settings
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory and Accreditation Requirements
    • 4.3.2 Shortage of Skilled Pathologists and Histotechnologists
    • 4.3.3 High Capital and Operating Costs of Advanced Systems
    • 4.3.4 Lack of Standardized Data Formats and Interoperability
  • 4.4 Regulatory Landscape
  • 4.5 Porter's Five Forces
    • 4.5.1 Threat Of New Entrants
    • 4.5.2 Bargaining Power Of Buyers
    • 4.5.3 Bargaining Power Of Suppliers
    • 4.5.4 Threat Of Substitute Products
    • 4.5.5 Intensity Of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product & Services
    • 5.1.1 Instruments
    • 5.1.2 Consumables
    • 5.1.3 Services
  • 5.2 By Application
    • 5.2.1 Disease Diagnosis
    • 5.2.1.1 Cancer
    • 5.2.1.2 Infectious Diseases
    • 5.2.1.3 Other Conditions
    • 5.2.2 Drug Discovery & Development
    • 5.2.2.1 Pre-Clinical Toxicology
    • 5.2.2.2 Companion Diagnostics
    • 5.2.2.3 Biomarker Validation
    • 5.2.3 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Diagnostic Laboratories
    • 5.3.3 Research Laboratories
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 F. Hoffmann-La Roche
    • 6.3.2 Danaher (Leica Biosystems)
    • 6.3.3 Thermo Fisher Scientific, Inc.
    • 6.3.4 Agilent Technologies, Inc.
    • 6.3.5 Sakura Finetek
    • 6.3.6 Quest Diagnostics Incorporated
    • 6.3.7 Laboratory Corporation of America Holdings
    • 6.3.8 NeoGenomics
    • 6.3.9 Cardinal Health
    • 6.3.10 BioGenex
    • 6.3.11 Bio SB
    • 6.3.12 3DHISTECH
    • 6.3.13 Philips Healthcare
    • 6.3.14 Ventana Medical Systems
    • 6.3.15 Indica Labs
    • 6.3.16 Hologic (Biocare)
    • 6.3.17 Sysmex
    • 6.3.18 PerkinElmer
    • 6.3.19 OptraSCAN
    • 6.3.20 Hamamatsu Photonics
    • 6.3.21 Microsoft (GigaPath)

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Anatomic Pathology Market Report Scope

As per the scope of the report, anatomic pathology is a medical specialty that is concerned with the diagnosis of disease based on the microscopic, macroscopic, biochemical, immunologic, and molecular examination of organs and tissues. Anatomic pathology involves the visualization of human tissue under a microscope for proper diagnosis of a disease or a pathological condition. Microscopic examination of tissue samples with the help of one or more stains is a standard procedure performed in anatomic pathology. The anatomic pathology market is segmented by products & services (instruments, consumables, and services), applications (disease diagnosis, drug discovery and development, and other applications), end users (hospitals, research laboratories, diagnostic laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product & Services Instruments
Consumables
Services
By Application Disease Diagnosis Cancer
Infectious Diseases
Other Conditions
Drug Discovery & Development Pre-Clinical Toxicology
Companion Diagnostics
Biomarker Validation
Other Applications
By End User Hospitals
Diagnostic Laboratories
Research Laboratories
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product & Services
Instruments
Consumables
Services
By Application
Disease Diagnosis Cancer
Infectious Diseases
Other Conditions
Drug Discovery & Development Pre-Clinical Toxicology
Companion Diagnostics
Biomarker Validation
Other Applications
By End User
Hospitals
Diagnostic Laboratories
Research Laboratories
Other End Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the anatomic pathology market?

The market stands at USD 38.34 billion in 2025 and is forecast to reach USD 56.65 billion by 2030.

Which product group holds the largest anatomic pathology market share?

Consumables lead with 46.54% revenue share in 2024 due to their recurring demand in every tissue-based test.

Why is Asia-Pacific the fastest growing region?

Growing healthcare expenditure, rising cancer incidence, and investment in digital laboratories are producing a 9.45% CAGR through 2030.

How are workforce shortages shaping technology adoption?

Vacancy rates above 10% are prompting laboratories to install automation, digital scanners, and AI to maintain throughput and diagnostic accuracy.

What role do companion diagnostics play in market growth?

Pharmaceutical reliance on biomarker-guided trials and targeted therapies is driving an 11.78% CAGR in the drug discovery and development segment.

Which recent FDA actions have accelerated digital pathology use?

Clearances for Epredia’s whole-slide system and Ibex Prostate Detect AI in 2025 provide regulatory confidence for primary digital diagnosis.

Page last updated on: June 28, 2025

Anatomic Pathology Market Report Snapshots